https://ezm0414inhibitor.com/y....our-scientific-great
Total death was 42%. The 24-hour death (25% vs 14% vs 35%; p= 0.042), in-hospital death (44% vs 29% vs 54%; p= 0.034), and 4-hour pRBC products transfused (15 [9-23] vs 10 [4-19] vs 16 [9-27]; p= 0.017) were low in the REBOA group. The REBOA team had faster times to both laparotomy (p= 0.04 and/or angioembolization (p= 0.012). There was clearly no distinction between the groups in acute renal damage, lower limb amputations, or hospital and ICU duration of stay among survivors. REBOA is a